Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri®in Greater China and Asia Pacific markets
New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment
Read more at prnewswire.com